MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
종목 코드 MXCT
회사 이름MaxCyte Inc
상장일Mar 29, 2016
CEOMr. Maher Masoud, J.D.
직원 수114
유형Ordinary Share
회계 연도 종료Mar 29
주소9713 Key West Avenue,
도시ROCKVILLE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호20850
전화13015175556
웹사이트https://www.maxcyte.com/
종목 코드 MXCT
상장일Mar 29, 2016
CEOMr. Maher Masoud, J.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음